Replimune to Acquire Aura BioSciences for $350M
Ticker: REPL · Form: 8-K · Filed: 2024-08-08T00:00:00.000Z
Sentiment: mixed
Topics: acquisition, biotech, oncology
Related Tickers: AURA
TL;DR
Replimune buying Aura BioSciences for $350M cash/stock to boost cancer therapy pipeline.
AI Summary
Replimune Group, Inc. announced on August 8, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of Aura BioSciences, Inc. for $350 million in cash and stock. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition aims to enhance Replimune's pipeline with Aura's novel viral immunotherapy platform.
Why It Matters
This acquisition could significantly expand Replimune's oncology pipeline and technological capabilities, potentially leading to new treatment options for cancer patients.
Risk Assessment
Risk Level: medium — The acquisition involves significant financial commitment and integration risks, and the success of the combined pipeline is not guaranteed.
Key Numbers
- $350 million — Acquisition Value (Total consideration for Aura BioSciences)
Key Players & Entities
- Replimune Group, Inc. (company) — Acquiring company
- Aura BioSciences, Inc. (company) — Target company
- $350 million (dollar_amount) — Acquisition price
- August 8, 2024 (date) — Announcement date
- fourth quarter of 2024 (date) — Expected closing date
FAQ
What is the total value of the transaction between Replimune Group, Inc. and Aura BioSciences, Inc.?
The total value of the transaction is $350 million in cash and stock.
When is the expected closing date for the acquisition?
The transaction is expected to close in the fourth quarter of 2024.
What is the primary strategic rationale for Replimune acquiring Aura BioSciences?
Replimune aims to enhance its pipeline with Aura's novel viral immunotherapy platform.
What are the key conditions for the closing of the acquisition?
The transaction is subject to customary closing conditions.
What type of therapy does Aura BioSciences specialize in?
Aura BioSciences specializes in viral immunotherapy.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-08-08 08:04:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Mar
Filing Documents
- tm2421132d1_8k.htm (8-K) — 27KB
- tm2421132d1_ex99-1.htm (EX-99.1) — 47KB
- 0001104659-24-087035.txt ( ) — 251KB
- repl-20240808.xsd (EX-101.SCH) — 3KB
- repl-20240808_lab.xml (EX-101.LAB) — 33KB
- repl-20240808_pre.xml (EX-101.PRE) — 22KB
- tm2421132d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 8, 2024, Replimune Group, Inc. (the "Company") issued a news release announcing its financial results for the first fiscal quarter ended June 30, 2024 and certain corporate updates. A copy of the news release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly stated by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 News Release dated August 8, 2024 104 Cover page interactive data file (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: August 8, 2024 By: /s/ Sushil Patel Sushil Patel Chief Executive Officer